


MultiMam™ Stable

**Generation of Multiprotein Expressing
Stable Mammalian Cell Lines**



User Manual

Version 2.3

December 2019

TABLE OF CONTENTS

A. MultiMam™ Stable Kit Contents	- 3 -
B. Introduction	- 4 -
Cellular interaction networks and protein complexes	- 4 -
Multiprotein expression tools.....	- 5 -
C. New Tools for Generation of Multiprotein Expressing Stable Mammalian Cell Lines	- 9 -
C.1. Transfer vectors: the Acceptor-Donor recombineering system.....	- 9 -
C.2. Generating multigene expression cassettes.....	- 13 -
C.2.1. Using the homing endonuclease/BstXI multiplication module	- 13 -
C.2.2. Multigene construction using Cre-Lox recombination.....	- 16 -
C.2.3. Combining HE/BstXI cycling and Cre-Lox recombination	- 17 -
D. Protocols.....	- 18 -
D.0 Introductory remarks	- 18 -
D.1 Cloning into pACEMam or pMDx transfer vectors	- 18 -
D.2 Multiplication by using the HE and BstXI sites	- 18 -
D.2.1. Protocol 1: Multiplication by using homing endonuclease/BstXI	- 19 -
D.3 Cre-LoxP reaction of Acceptors and Donors	- 21 -
D 3.1. Protocol 2: Cre-LoxP fusion of Acceptors and Donors	- 21 -
D 3.2. Protocol 3: Deconstruction of fusion vectors by Cre	- 24 -
D 4. Generation of stable cell lines	- 24 -
D 4.1 Protocol 4: Generation of stable cell lines	- 24 -
E. Appendix	- 29 -
E.1. Preparing bacterial stock from agar stabs	- 30 -
E.2. MultiMam™ Stable vectors: maps, sequences, MCS, restriction	- 31 -
E.2.1 Acceptor vectors	- 32 -
E.2.1.1 pACEMam1: 3443 bp	- 32 -
E.2.1.2 pACEMam2: 4618 bp	- 35 -
E.2.1.3 pACEMam3/Integrator Module: 6954 bp.....	- 35 -
E.2.2 Donor vectors.....	- 41 -
E.2.2.1 pMDC: 2889 bp	- 41 -

E.2.2.2 pMDK: 4130 bp	- 44 -
E.2.2.3 pMDS: 4088 bp.....	- 47 -
F. References.....	- 50 -
G. Purchaser Notification	- 52 -

MultiMam™ Stable Kit Contents

- **Plasmid acceptor vector**

pACEMam3/Integrator Module approx. 5 µg DNA per vial (in buffer solution)

keep at 4°C for short-term storage and in a freezer at -20°C or lower for medium- and long-term storage (take care to avoid repeated freeze-thaw cycles, e.g. by aliquotting DNA prior to freezing)

- **Plasmid donor vectors**

pMDC, pMDK, pMDS; approx. 5 µg DNA per vial (in buffer solution)

keep at 4°C for short-term storage and in a freezer at -20°C or lower for medium- and long-term storage (take care to avoid repeated freeze-thaw cycles, e.g. by aliquotting DNA prior to freezing)

- **E. coli strains as agar stabs**

pirHC, pirLC cells[†]

For propagation and amplification of donor multigene expression constructs or donor-donor fusions

Keep agar stabs at 4°C or at RT; **do not freeze!** We recommend to immediately prepare stocks from streaked bacterial colonies (see p. 26).

[†] *E. coli* strains expressing the *pir* gene for propagation of donor vectors (any other strain with *pir*⁺ background can be used as well). LC: low copy number propagation, HC: high copy number propagation of plasmids with R6K γ origin.

Reagents to be supplied by the user (see also Section D. Protocols)

- Restriction enzymes and Homing endonucleases PI-SceI and I-CeuI
- Mammalian cells, e.g. HEK293, CHO, etc.
- T4 DNA ligase
- Cre recombinase
- Standard *E. coli* strains for cloning (such as TOP10, DH5 α , HB101 etc.)
- Standard laboratory buffers, solutions, media and equipment for bacterial and mammalian cell culture, transformation etc.
- Commercially available transfection reagents, e.g. FuGENE® (Roche), jetPEI™ (Polyplus transfection), etc. or an apparatus for electroporation
- Antibiotics

B. Introduction

Cellular interaction networks and protein complexes

In 1998, Bruce Alberts confronted conventional thinking that predicated on the action of individual proteins on Beadle and Tatum's one-gene/one-enzyme hypothesis (published in 1941) which for decades had shaped much of biological research. Instead, Alberts asked us to direct our focus to a modular cellular machinery composed of protein complexes (Alberts, 1998).

Proteins are the physical representatives of the information encoded by their corresponding genes and mRNAs. They are themselves embedded into a tightly and intricately regulated DNA-RNA-network (Vidal et al., 2011). These proteins determine many structural and physiological properties of cells but rarely act in isolation to mediate their effects. More often than not they will have multiple partners - not only proteins but also nucleic acids and small molecules – which they bind or bind to or associate with in larger complexes. Whether you look at replication, transcription, translation, transport processes across internal and external membranes, signaling events, etc. - protein complexes come into play in all of these processes. More importantly, such complexes – if disrupted by mutations or the like - also engender often severe physiological deficits (Ehmsen et al., 2002; Vidal et al., 2011). Some of these complexes will, by their functional nature, either be long-lived ("stable") or transitory. Fleeting interaction of proteins, e.g. in cell signaling, will result in only minute amounts of a protein complex that usually also exists for only a limited period of time.

Deconvoluting this social life of the cell (Robinson et al., 2007) is a daunting task but has been tackled with high resolution imaging and analysis techniques (cryoEM, X-ray crystallography, NMR, mass spectroscopy, etc.). Extensive bioinformatics work-up and computer modeling support the experimental structural biology work and contribute to solving complex multisubunit assemblies down to the atomic level (e.g. Imasaki et al., 2011). All these results enter into a better understanding of molecular interactions between proteins and other macromolecules, now known as the **interactome** (Figeyns, 2008; Charbonnier et al., 2008) and their effects on the biological system of the cell.

Multiprotein expression tools

The role of protein interaction networks (the so-called interactome) has become an intense focus of biological research efforts in the post-genomic era. Many of the identified multiprotein complexes, or interaction networks are expressed at only low abundance in their native cells. This makes analysis of their structure or function difficult, but this can be remedied by using recombinant technologies to facilitate large-scale heterologous protein production. In addition modern biopharmaceutical manufacturing, and synthetic biology applications require multiprotein expression technologies. Various heterologous systems have been developed for the major production/host organisms *E.coli*, yeast, insect and mammalian cells. While sophisticated systems for expressing individual proteins exist, the repertoire of tools for multiprotein expression to date is rather limited (e.g, Bieniossek et al. 2009; Trowitzsch et al., 2010), especially for mammalian cells.

Co-transfection, whether by biochemical or physical means, or through viruses, still is the method of choice when it comes to delivering multiple genes of interest into mammalian cells. Co-transfection often fails to warrant uniform and constant expression of all vectors in one transfection experiment. Stable transfection remedies this problem to a certain degree but is cumbersome and requires multiple rounds of selection and re-culturing to yield uniform and stable clones and is a process that typically requires weeks to months. In addition, and critically, expression from stable cell lines cannot easily be adjusted once the stable cell line is generated. Vector systems that improve stable transfection of multiple genes are in demand for mammalian cells. **This manual introduces a technology called MultiMam™ Stable which enables generation of stable multiprotein-expressing mammalian cell lines, where the relative stoichiometry of individual expression cassettes is controllable on a DNA level.**

Currently, recombinant expression methods require a disproportionate investment in both labor and materials prior to multiprotein expression, and, once expression has been established, provide little or no flexibility for rapidly altering the multiprotein components, which is a prerequisite for revising expression studies. The mammalian expression system introduced here (see also Vijayachandran et al., 2011) boasts two major advances that are instrumental in fully exploiting the potential of this heterologous protein production system:

1) New transfer vectors (pACEMam1, pACEMam2, pACEMam3/Integrator Module, pMDC, pMDK, pMDS; see Figure 1) that contain a homing endonuclease-based multiplication module. These vectors greatly facilitate modular combination of heterologous genes (in their respective gene expression cassettes) with a minimum requirement for unique restriction sites (BstXI). Strong viral/mammalian promoters (currently CMV and the hybrid CAG promoters) can be exchanged in our vectors for other promoter sequences if desired. Likewise, terminator sequences (currently SV40, rabbit β-actin) can be substituted as required.




Figure 1: Schematic representation of the MultiMam™ *Stable* acceptor and donor vectors. More detailed vectors maps and sequence information can be found in Chapter C and in the Appendix.

2) New protocol for rapid generation of multigene expression constructs via Cre-LoxP recombineering. The resulting multigene fusion can then be transfected directly into mammalian cells for stable expression. This protocol can be used to integrate multigene

cassettes with coding sequences for multiprotein complex subunits but also to integrate specific enzymes (kinases, acetylases etc.) for modifying the proteins under investigation.




Figure 2a: Schematic overview of the MultiMam™ Stable system

Genes of interest are assembled into multigene expression cassettes using the multiplication module present on the donor (pMDC, pMDK, pMDS) and acceptor vectors (pACEMam1, pACEMam2, Integrator Module). Acceptor-donor fusions can then be generated by Cre-LoxP recombination. These multigene fusions contain one Acceptor and one to several Donor vectors, each with one or several genes of interest (here A-H). Desired Acceptor-Donor combinations are identified by transformation into *E.coli* and subsequent antibiotic selection. *LoxP* sites in the acceptor-donor fusions have been omitted for reasons of clarity.




Figure 2B: Generation of multigene donor constructs through Cre-Lox fusion.


As indicated in Figure 2A, donor multigene expression cassette constructs can also be generated by Cre-Lox recombination. Individual or multiple gene cassettes are cloned into the multiple cloning site via standard restriction-ligation cloning or, when introducing multiple gene cassettes, homing endonuclease /BstXI cloning. The gene cassettes harbored on different donor vectors are then merged into a single vector construct via Cre-Lox recombination. This construct will differ from the multigene constructs in Figure 2a with respect to selective markers. While the multigene construct in Figure 2A carries only one antibiotic resistance marker, the construct in Figure 2B will carry three, one from each donor vector. This will allow selection of multigene constructs with higher stringency by subjecting the constructs to a multi-antibiotic selection regimen (refer to protocol 2). *LoxP* sites in the donor fusion have been omitted for reasons of clarity.

C. New Tools for Multigene Applications in Mammalian Cells

C.1. Transfer vectors: the Acceptor-Donor recombineering system.

The **Acceptor vectors** pACEMam1 and pACEMam2 contain multiple cloning sites (MCS; see appendix) flanked by either a CMV or CAG promoter to drive high-level expression in mammalian cells. Wherever necessary, appropriate polyA signal sequences are available (SV40 late for pACEMam1).

A multiplication module M – defined by the homing endonuclease site I-Ceu and a corresponding BsXI site (see Figure 3A) – allows integration of multiple gene cassettes (ORFs and associated regulatory regions).






Figure 3B: Circle map representation of pACEMam3/Integrator Module


In Figure 3B, pACEMam3/Integrator module is shown schematically. This is the vector which drives integration of multiprotein expression cassettes into the mammalian genome. It is absolutely REQUIRED for generation of stable integrants so please take care to use this vector in your The vector contains a Zeocin resistance marker to drive selection of stable integrants and gene amplification. It also contains a YFP expression cassette driven by a mammalian promoter to allow for monitoring of successful genome integration events, and relative expression yield, via fluorescence.

The **Donor vectors** pMDC, pMDS, pMDK are similar to the acceptor vectors with respect to their over-all design. The multiple cloning site is bracketed by a multiplication element (in this case, PI-SceI / BstXI) to enable concatenation of inserts between the different donor vectors. Vectors also

contain a LoxP incomplete inverted repeat to create acceptor-donor or donor-donor fusions. The vectors contain “tell-tale” resistance markers (pMDC: chloramphenicol, pMDK: kanamycin, pMDS: spectinomycin) and, importantly, a conditional R6K γ origin of replication which makes propagation of the donor vectors dependent on the expression of the *pir* gene in the prokaryotic host (such as the pirLC and pirHC cells contained in the kit).

Figure 4: Circle map representation of Donor vectors a) a) pMDC, b) pMDK, c) pMDS.

Circle maps show promoters (CMV, CAG), terminators (SV40, rabbit β -globin), multiple cloning sites (MCS), the incomplete inverted repeat for *cre-lox* site-specific recombination (LoxP) and resistance markers (chloramphenicol, kanamycin, and spectinomycin, respectively). Genes of interest are cloned into the MCS using unique restriction sites. The multiplication module consists of the homing endonuclease site PI-SceI and the restriction endonuclease site BstXI. All donor vectors host a conditional R6K γ origin of replication.



The MultiMam™ Stable system vectors in their current form do not contain DNA sequences that code for affinity tags (that will facilitate purification or solubilization of the protein(s) of interest). Tags that are typically used are C- or N-terminal oligohistidine tags, with or without protease cleavage sites for tag removal. They can be introduced by designing the respective PCR primers used for amplification of the genes of interest. We recommend outfitting Donors or Acceptors of choice with

any custom tag that is favored in individual user laboratories prior to inserting recombinant genes of interest. This is best done by using a design that will, after tag insertion, still be compatible with the recombination-based principles of MultiMam™ Stable system usage.

The same holds true for reporter genes, most notably fluorescent proteins that are commonly used in protein localization or protein interaction studies. These can also be fused to your protein under investigation using PCR techniques.

C.2. Generating multigene expression cassettes

C.2.1. Using the homing endonuclease/BstXI multiplication module

The acceptor and donor vectors are suited for generating multigene expression cassettes from individual gene expression cassettes (complete with regulatory regions such as promoter and terminator) via a multiplication module bracketing the multiple cloning site (MCS). All MultiMam™ Stable vectors contain a homing endonuclease (HE) site and a correspondingly designed *Bst*XI site that together bracket the MCS. Homing endonucleases have long recognition sites (20-30 base pairs or more). Although not all equally stringent, homing endonuclease sites are very likely unique in the context of even large plasmids, or, in fact, entire genomes.

The logic of multiplication is illustrated below. The homing endonuclease site can be used to insert entire expression cassettes into a vector that already contains one gene or several genes of interest as separate expression cassettes. The only prerequisite for assembling multigene expression cassettes is that the homing endonucleases and restriction enzymes used for multiplication (*I-Ceu*I/*Pi-Sce*I and *Bst*XI) are unique, which can be easily accomplished, for instance by site-directed mutagenesis prior to multigene cassette assembly. First, individual genes are cloned into the multiple cloning sites of the acceptor and donor vectors. The entire expression cassette, including promoter and terminator, is then excised by *I-Ceu*I / *Bst*XI (acceptors) or *Pi-Sce*I / *Bst*XI (donors) digestion. The resulting fragment is placed into the multiplication module of another acceptor or donor vector containing single or multiple gene cassettes. The restriction sites involved are eliminated in the process and multiplication can be repeated iteratively using the module present in the inserted cassette. Moreover, promoter and terminator sequences can be easily modified if desired using appropriate restriction sites in our vectors.

- !** Please note that multiplication cannot be accomplished from donors to acceptors and vice versa since the overhangs generated by endonuclease digestion are incompatible.





Figure 5: Assembling individual gene cassettes into multigene expression cassettes. The logic of multiplication is shown schematically. The expression cassette containing the gene of choice (denoted as GOI2 in this case) is excised by digestion with the homing endonuclease (red box) and BstXI (green box). For acceptor vectors, I-CeuI is the homing endonuclease of choice, and for donor vectors PI-SceI. The plasmid vector harboring the GOI1-cassette only needs to be linearized with BstXI. The homing endonucleases produce cohesive ends that are compatible with the ends generated by the BstXI digest. Upon insertion of GOI2 into the target vector, a homing endonuclease/BstXI hybrid restriction site is created that can then cannot be cut by either enzyme (crossed-out red/green box) while the 3'-BstXI site is regenerated. The same procedure can be repeated over and over as exemplified by the integration of GOI3. This cycling logic can be used to generate multigene assemblies. Note that the promoters and terminators are not explicitly shown for reasons of clarity.

A



B




Figure 6: Combining multigene expression cassettes. Different multigene expression cassettes can be combined into one expression construct following the same logic that applies to the generation of multigene expression cassettes from individual gene cassettes (Figure 4). The 5' homing endonuclease recognition site (filled red box) will be preserved if GOI1 has been introduced by conventional restriction cloning into the MCS. Promoters and terminators are not explicitly shown for reasons of clarity but flank the GOIs in every individual gene expression cassette.

C.2.2. Multigene construction using Cre-Lox recombination

Cre recombinase is a member of the integrase family (Type I topoisomerase from bacteriophage P1). It recombines a 34 bp loxP site in the absence of accessory protein or any auxiliary DNA sequence. The loxP site is comprised of two 13 bp recombinase-binding elements arranged as inverted repeats which flank an 8 bp central region where cleavage and the ligation reaction occur.

The site-specific recombination mediated by Cre recombinase involves the formation of a Holliday junction (HJ). The recombination events catalyzed by Cre recombinase depend on the location and relative orientation of the loxP sites. Two DNA molecules, for example an acceptor and a donor plasmid, containing single loxP sites will be fused. Furthermore, the Cre recombination is an equilibrium reaction with 20-30% efficiency in recombination. This provides useful options for multigene combinations for multiprotein complex expression.




Figure 7: LoxP imperfect inverted repeat

In a reaction where several DNA molecules such as donors and acceptors are incubated with Cre recombinase, the fusion/excision activity of the enzyme will result in an equilibrium state where single vectors (educt vectors) and all possible fusions coexist. Donor vectors can be used with acceptors and/or donors, and vice versa. Higher order fusions are also generated where more than two vectors are fused. This is shown schematically in Figure 8.

The fact that Donors contain a conditional origin of replication that depends on a *pir*⁺ (*pir* positive) background now allows for selecting out from this reaction mix all desired Acceptor-Donor(s) combinations. For this, the reaction mix is used to transform *pir* negative strains (TOP10, DH5 α , HB101 or other common laboratory cloning strains). Then, Donor vectors will act as suicide vectors when plated out on agar containing the antibiotic corresponding to the Donor encoded resistance marker, unless fused with an Acceptor. By using agar with the appropriate combinations of antibiotics, all desired Acceptor-Donor fusions can be selected for.




Figure 8: Cre and De-Cre reaction pyramid

Cre-mediated assembly and disassembly of pACEMam1, pMDK, and pMDS vectors are shown in a schematic representation (left). LoxP sites are shown as red circles, resistance markers and origins are labeled. White arrows stand for the entire expression cassette (including promoter, terminator and gene integration/multiplication elements) in the MultiMam™ Stable vectors. Not all possible fusion products are shown for reasons of clarity. Levels of multi-resistance are indicated (right column).

C.2.3. Combining HE/BstXI cycling and Cre-Lox recombination

Both methods can also be combined to generate multiple gene-expression cassette constructs. To this end, you can introduce multiple gene cassettes with the homing endonuclease/BstXI protocol into different Acceptor/Donor vectors and then fuse these using the Cre-Lox modules (illustrated in Figure 2a).

D. Protocols

D.0 Introductory remarks

Please note that the bacteria in the agar stabs have not been made competent for transformation. If you wish to use them to transform your constructs, you will have to prepare competent cells. This applies specifically to the pirHC and pirLC strains used to maintain donor constructs. You may follow your preferred protocol for preparing chemically or electrocompetent cells, e.g. Inoue et al. (1990) or variations of this protocol, or standard protocols as described in Current Protocols in Molecular Biology or Sambrook and Russell: Molecular Cloning (3rd edition, 2001, or older versions).

D.1 Cloning into pACEMam or pMDx transfer vectors

Reagents:

Restriction endonucleases

DNA ligase

E. coli competent cells

Antibiotics: Chloramphenicol, Gentamycin, Kanamycin, Spectinomycin

The genes of choice are cloned using standard cloning procedures into the multiple cloning sites MCS (see *Supplementary Information*) of pACEMam1/2 and pMDC, pMDK, pMDS. Ligation reactions for pACEMam derivatives are transformed into standard *E. coli* cells for cloning (such as TOP10, DH5 α , HB101) and plated on agar containing gentamycin (7 μ g/ml). Ligation reactions for pIDx derivatives are transformed into *E. coli* cells expressing the *pir* gene (pirHC and pirLC from this kit – in this case you will need to make the cells electro- or chemically competent first; other strains, e.g. BW23473, BW23474) and plated on agar containing chloramphenicol (pMDC; 25 μ g/ml), kanamycin (pMDK; 50 μ g/ml) or spectinomycin (pMDS; 50 μ g/ml). Correct clones are selected based on specific restriction digestion patterns and DNA sequencing of the inserts.

D.2 Multiplication by using the HE and BstXI sites

MultiMam™ Stable donor vectors contain a recognition site for the homing endonuclease PI-SceI (fig. 3). Upon cleavage, this HE site yields a 3' overhang with the sequence -GTGC. Acceptor vectors contain the homing endonuclease site I-CeuI (see fig. 2), which upon cleavage will result in a 3' overhang of -

CTAA. On acceptors and donors, the respective HE site precedes the MCS (see Figure 2). The 3' end of the MIE contains a specifically designed BstXI site, which upon cleavage will generate a matching overhang. The basis of this is the specificity of cleavage by BstXI. The recognition sequence of BstXI is defined as CCANNNNN'NTGG (the apostrophe marks the position of the phosphodiester link cleavage). The residues denoted as N can be chosen freely. Donor vectors thus contain a BstXI recognition site with the sequence CCATGTGC'CTGG, and Acceptor vectors contain CCATCTAA'TTGG. The overhangs generated by BstXI cleavage in each case will match the overhangs generated by HE cleavage. Note that Acceptors and Donors have different HE sites.

The recognition sites are not symmetric. Therefore, ligation of a HE/BstXI digested fragment into a HE site of an MultiMam™ Stable vector will be (1) directional and (2) result in a hybrid DNA sequence where a HE halfsite is combined with a BstXI half site (see Figure 5). This site will be cut by neither the HE nor BstXI. Therefore, in a construct that has been digested with a HE, insertion by ligation of HE/BstXI digested DNA fragment containing an expression cassette with one or several genes will result in a construct which contains all heterologous genes of interest, enveloped by an intact HE site in front, and a BstXI site at the end. Therefore, the process of integrating entire expression cassettes by means of HE/BstXI digestion and ligation into a HE site can be repeated iteratively.

D.2 Protocol 1. Multiplication by using homing endonuclease/BstXI.

Reagents required:

Homing endonucleases PI-SceI, I-CeuI
10x Buffers for homing endonucleases
Restriction enzyme BstXI (and 10x Buffer)
T4 DNA ligase (and 10x Buffer)
E. coli competent cells
Antibiotics

Step 1: Insert preparation

Restriction reactions are carried out in 40 µl reaction volumes, using homing endonucleases PI-SceI (Donors) or I-CeuI (Acceptors) as recommended by the supplier.

Acceptor or donor plasmid ($\geq 0.5 \mu\text{g}$) in ddH ₂ O	32 µl
--	-------

10x restriction enzyme buffer	4 µl
10 mM BSA	2 µl
PI-SceI (Donors) or I-Ceul (acceptors)	2 µl

Reactions are then purified using a PCR extraction kit or by acidic ethanol precipitation, and subsequently digested with BstXI according to the supplier's recommendations.

HE digested DNA in ddH ₂ O	32 µl
10x restriction enzyme buffer	4 µl
10 mM BSA	2 µl
BstXI	2 µl

Gel extraction of insert(s):

Processed insert is then purified by agarose gel extraction using commercial kits (Qiagen, Macherey Nagel etc). Elution of the extracted DNA in the minimal volume defined by the manufacturer is recommended.

Step 2: Vector preparation

Restriction reactions are carried out in 40 µl reaction volumes, using homing endonucleases PI-SceI (Donors) or I-Ceul (Acceptors) as recommended by the supplier.

Acceptor or donor plasmid ($\geq 0.5 \mu\text{g}$) in ddH ₂ O	33 µl
10x Restriction enzyme buffer	4 µl
10 mM BSA	2 µl
BstXI	2 µl

Reactions are then purified by PCR extraction kit or acidic ethanol precipitation, and next treated with intestinal alkaline phosphatase according to the supplier's recommendations. Dephosphorylation is performed to minimize vector re-annealing and to increase integration of the insert.

HE digested DNA in ddH ₂ O	17 µl
10x Alkaline phosphatase buffer	2 µl
Alkaline phosphatase	1 µl

Gel extraction of vector:

Processed vector is then purified by agarose gel extraction using commercial kits (Qiagen, MachereyNagel etc). Elution of the extracted DNA in the minimal volume defined by the manufacturer is recommended.

Step 3: Ligation

Ligation reactions are carried out in 20 µl reaction volumes:

HE/Phosphatase treated vector (gel extracted)	4 µl
HE/BstXI treated insert (gel extracted)	14 µl
10x T4 DNA Ligase buffer	2 µl

T4 DNA Ligase 0.5 µl

Ligation reactions are performed at 25°C for 1h or at 16°C overnight.

Step 4: Transformation

Mixtures are next transformed into competent cells following standard transformation procedures.

Ligation reactions for pACEMam1 and pACEMam2 derivatives are transformed into standard *E. coli* cells for cloning (such as TOP10, DH5 α , HB101) and, after recovery, are plated on agar containing gentamycin (7 µg/ml).

Reactions for Donor derivatives are transformed into *E. coli* cells expressing the *pir* gene (such as BW23473, BW23474, or PIR1 and PIR2 from Invitrogen and, of course, pirLC and pirHC in this kit) and plated on agar containing chloramphenicol (25 µg/ml, pMDC), kanamycin (50 µg/ml, pMDK), or spectinomycin (50 µg/ml, pMDS).

Step 5: Plasmid analysis

Plasmids are cultured and correct clones selected based on specific restriction digestion and DNA sequencing of the inserts.

D.3 Cre-LoxP reaction of Acceptors and Donors

D 3.1. Protocol 2: Cre-LoxP fusion of Acceptors and Donors

This protocol is designed for generating multigene fusions from Donors and Acceptors by Cre-LoxP reaction.

Reagents:

Cre recombinase (from NEB or self-made)

Standard *E. coli* competent cells (*pir* strain)

Antibiotics

96-well microtiter plates

12 well tissue-culture plates (or Petri dishes) w. agar/antibiotics

LB medium

1. For a 20 µl Cre reaction, mix 1-2 µg of each educt in approximately equal amounts. Add ddH₂O to adjust the total volume to 16-17 µl, then add 2 µl 10x Cre buffer and 1-2 µl Cre recombinase (1-2 U) .
2. Incubate Cre reaction at 37°C (or 30°C) for 1 hour.
3. Optional: load 2-5 µl of Cre reaction on an analytical agarose gel for examination.

Heat inactivation at 70°C for 10 minutes before gel loading is strongly recommended.

4. For chemical transformation, mix 10-15 µl Cre reaction with 200 µl chemically competent cells. Incubate the mixture on ice for 15-30 minutes. Then perform heat shock at 42°C for 45-60 s.

Up to 20 µl Cre reaction (0.1 volumes of the chemically competent cell suspension) can be directly transformed into 200 µl chemical competent cells.

For electrotransformation, up to 2 µl Cre reaction can be directly mixed with 100 µl electrocompetent cells, and transformed by using an electroporator (e.g. BIORAD *E. coli* Pulser) at 1.8-2.0 kV.

Larger volumes of Cre reaction must be desalted by ethanol precipitation or via PCR purification columns before electrotransformation. The desalted Cre reaction mix should not exceed 0.1 volumes of the electrocompetent cell suspension.

The cell/DNA mixture can be immediately used for electrotransformation without prolonged incubation on ice.

5. Add up to 400 µl of LB (or SOC) medium per 100 µl of cell/DNA suspension immediately after the transformation (heat shock or electroporation).

6. Incubate the suspension in a 37°C shaking incubator overnight or for at least 4 hours (recovery period).

To recover multifusion plasmid containing more than 2 resistance markers, it is strongly recommended to incubate the suspension at 37°C overnight.

7. Plate out the recovered cell suspension on agar containing the desired combination of antibiotics. Incubate at 37°C overnight.

8. Clones from colonies present after overnight incubation can be verified by restriction digestion at this stage (refer to steps 12-16).

This quality control step should be carried out especially in the case that only one specific multifusion plasmid is desired.


For further selection by single antibiotic challenges on a 96 well microtiter plate, continue to step 9.

Several to many different multifusion plasmid combinations can be processed and selected in parallel on one 96 well microtiter plate.

9. For 96 well antibiotic tests, inoculate four colonies from each agar plate with different antibiotic combinations into approx. 500 µl LB medium without antibiotics. Incubate the cell cultures in a 37°C shaking incubator for 1-2 hours.

10. While incubating the colonies, fill a 96-well microtiter plate with 150 µl antibiotic-containing LB medium (following Illustration 7). It is recommended to add coloured dye (positional marker) in the wells indicated.


A typical arrangement of the solutions, which is used for parallel selections of multifusion plasmids, is shown in Figure 9. The concept behind the 96 well plate experiment is that every cell suspension from single colonies needs to be challenged by all four single antibiotics for unambiguous interpretation.



11. Add 1 μ l aliquots of pre-incubated cell culture (Step 9) to the corresponding wells. Then incubate the inoculated 96 well microtiter plate in a 37°C shaking incubator overnight at 180-200 rpm.
- Recommended: use parafilm or any other adhesive seal to wrap the plate to avoid drying out.
The remainder of the pre-incubated cell cultures can be kept at 4°C for further inoculations if necessary.*
12. Select transformants containing desired multifusion plasmids based on antibiotic resistance, according to the combination of dense (positive) and clear (no growth) cell microcultures from each colony. Inoculate 10-20 μ l cell culture into 10 ml LB media with corresponding antibiotics. Incubate in a 37°C shaking incubator overnight.
 13. Centrifuge the overnight cell cultures at 4000g for 5-10 minutes. Purify plasmid from the resulting cell pellets with common plasmid miniprep kits, according to manufacturer's recommendation.
 14. Determine the concentrations of purified plasmid solutions by using UV absorption spectrophotometry (e.g. by using a NanoDrop™ 1000 machine).
 15. Digest 0.5-1 μ g of the purified plasmid solution in a 20 μ l restriction digestion with appropriate endonuclease(s). Incubate under recommended reaction condition for approx. 2 hours.
 16. Use 5-10 μ l of the digestion for analytical agarose (0.8-1.2%) gel electrophoresis. Verify plasmid integrity by comparing the experimental restriction pattern to a restriction pattern predicted *in silico* (e.g. by using program Snapgene, VectorNTI or similar programs).

D 3.4. Protocol 3. Deconstruction of fusion vectors by Cre

The following protocol is suitable for releasing any single educt from multifusion constructs (deconstruction). This is achieved by Cre-LoxP reaction, transformation and plating on agar with appropriately reduced antibiotic resistance level (cf. Figure 10). In the liberated educt entity, encoding genes can be modified and diversified. Then, the diversified construct is resupplied by Cre-LoxP reaction (C3.1).



Reagents:

Cre recombinase (and 10x Buffer)

E. coli competent cells

(*pir*⁺ strains, *pir*⁻ strains can be used only when partially deconstructed Acceptor-Donor fusions are desired).

Antibiotics

1. Incubate approx. 1 µg multifusion plasmid with 2 µl 10x Cre buffer, 1-2 µl Cre recombinase, add ddH₂O to adjust the total reaction volume to 20 µl.
2. Incubate this Cre deconstruction reaction mixture at 30°C for 1 to 4 hour(s).
3. Optional: load 2-5 µl of the reaction on an analytical agarose gel for examination.

Heat inactivation at 70°C for 10 minutes before gel loading is strongly recommended.

4. For chemical transformation, mix 10-15 μ l De-Cre reaction with 200 μ l chemically competent cells. Incubate the mixture on ice for 15-30 minutes. Then perform heat shock at 42°C for 45-60 s.

Up to 20 μ l De-Cre reaction (0.1 volumes of the chemical competent cell suspension) can be directly transformed into 200 μ l chemically competent cells.

For electrotransformation, up to 2 μ l De-Cre reaction can be directly mixed with 100 μ l electrocompetent cells, and transformed by using an electroporator (e.g. BIORAD *E. coli* Pulser) at 1.8-2.0 kV.

Larger volume of De-Cre reaction must be desalted by ethanol precipitation or PCR purification column prior to electrotransformation. The desalted De-Cre reaction mix should not exceed 0.1 volumes of the electrocompetent cell suspension.

The cell/DNA mixture can be immediately used for electrotransformation without prior incubation on ice.

5. Add up to 400 μ l of LB media (or SOC media) per 100 μ l of cell/DNA suspension immediately after the transformation (heat shock or electroporation).

6. Incubate the suspension in a 37°C shaking incubator (recovery).

For recovery of partially deconstructed double/triple fusions, incubate the suspension in a 37°C shaking incubator for 1 to 2 hours.

For recovery of individual educts, incubate the suspension in a 37°C shaking incubator overnight or for at least 4 hours.

7. Plate out the recovered cell suspension on agar containing the desired (combination of) antibiotic(s). Incubate at 37°C overnight.

8. Colonies after overnight incubation can be verified directly by restriction digestion at this stage (refer to steps 12-16).

This is especially recommended in cases where only a single educt or partially deconstructed multifusion plasmid is desired.

For further selection by single antibiotic challenge on a 96 well microtiter plate, continue with step 9.

Several different single educts/partially deconstructed multifusion plasmids can be processed and selected in parallel on one 96 well microtiter plate.

9. For 96 well analysis, inoculate four colonies each from agar plates containing a defined set of antibiotics into approx. 500 μ l LB medium without antibiotics. Incubate the cell cultures in a 37°C shaking incubator for 1-2 hours.

10. While incubating the colonies, fill a 96 well microtiter plate with 150 μ l antibiotic-containing LB medium or dye (positional marker) in the corresponding wells.

Refer to Figures 9 and 10 for the arrangement of the solutions in the wells, which are used for parallel selection of single educts or partially deconstructed multifusion plasmids. The concept is that every cell suspension from a single colony needs to be challenged by all four antibiotics separately for unambiguous interpretation.

11. Add 1 μ l aliquots from the pre-incubated cell cultures (Step 9) into the corresponding wells. Incubate the 96 well microtiter plate in a 37°C shaking incubator overnight at 180-200 rpm.

Recommended: use parafilm to wrap the plate to prevent desiccation.

The remainder of the pre-incubated cell cultures can be kept at 4°C in a refrigerator for further inoculations if necessary.


12. Select transformants containing desired single educts or partially deconstructed multifusion plasmids according to the combination of dense (growth) and clear (no growth) cell cultures from each colony. Inoculate 10-20 µl from the cell cultures into 10 ml LB media with corresponding antibiotic(s). Incubate in a 37°C shaking incubator overnight.
13. The next day, centrifuge the overnight cell cultures at 4000g for 5-10 minutes. Purify plasmid from cell pellets with common plasmid miniprep kits, according to manufacturers' protocols.
14. Determine the concentrations of purified plasmid solutions by using UV absorption spectroscopy (e.g. NanoDrop™ 1000).
15. Digest 0.5-1 µg of the purified plasmid solution in a 20 µl restriction digestion (with 5-10 units endonuclease). Incubate under recommended reaction condition for approx. 2 hours.
16. Use 5-10 µl of the digestion for analytical agarose gel (0.8-1.2%) electrophoresis. Verify plasmid integrity by comparing the *de facto* restriction pattern to the *in silico* predicted restriction pattern (e.g. by using VectorNTI, Invitrogen, or any other similar program).
17. Optional: Occasionally, a deconstruction reaction is not complete but yields partially deconstructed fusions which still retain entities to be eliminated. In this case, we recommend to pick these partially deconstructed fusions containing and perform a second round of Cre deconstruction reaction (repeat steps 1-8) by using this construct as starting material.

D 4. Generation of stable cell lines

Generation of stable mammalian cell lines with the MultiMam™ *Stable* fusion DNA's generated from e.g. D2.3 above requires three distinct processes :

- I. Linearization of MultiMam™ *Stable* fusion DNA via homing endonuclease PI-PspI, or I-SceI.

These enzymes will linearize the multigene (multiplasmid) fusion construct, with an antibiotic selection marker at each end (see map of pACEMam3/Integrator Module below). *Note: As an alternative to transfecting linearized MultiMam™ Stable fusion DNA into e.g. HEK-293 cells, the FRT site in pACEMam3/Integrator Module makes our system compatible with the Flp-In™-293 Cell Line (Life Tech).*



- II. Transfection of linearized MultiMam™ *Stable* fusion DNA into your mammalian cell line of interest.
- III. Selection of stable cell lines, a process where your MultiMam™ *Stable* fusion DNA integrates into the host cell chromosome, and then forms tandem repeats via DNA recombination, driven by antibiotic selection. Key to this process also is the pACEMam3/Integrator Module plasmid shown above. The vector contains both a Zeocin resistance marker, and a Hygromycin marker, to drive selection of stable integrants and gene amplification. Use of two markers

rather than one also helps stabilize the DNA during tandem expansion to protect against deletions. pACEMam3/Integrator Module also contains an eYFP expression cassette driven by a mammalian promoter to allow for monitoring of successful genome integration events, and relative expression yield, via fluorescence. We recommend concentrations of Zeocin + Hygromycin using the specific antibiotic manufacturer's instructions.

D 4.1 Protocol 4: Generation of stable cell lines

This protocol is designed for generating stable cell lines from MultiMam™ *Stable* fusion DNA created e.g. via D3.1. Successful creation of multiprotein expressing stable cell lines is confirmed conveniently via fluorescence.

Reagents:

Homing endonucleases PI-Pspl, or I-SceI
10cm cell culture dishes
Standard cell culture cell culture pipettes
Mammalian cell line
PBS/HBSS
Gibco™ Opti-MEM™ or preferred mammalian cell culture media
DMEM medium
FuGENE® 6 Transfection Reagent or preferred substitute
Antibiotics Zeocin + Hygromycin

1. Digest 3.5ug multigene fusion DNA containing pACEMam3/Integrator Module with PI-Pspl, or I-SceI according to the manufacturer's instructions. *Note: if using the Flp-In™-293 Cell Line (Life Tech), and follow the Flp-In™-293 Cell Line manufacturer's instructions for DNA integration, and proceed to step 9*
2. In 10 cm dish, use HEK-293 cells in DMEM medium that are 50-60% confluent and have not reached 100% confluency at any time in the last 3 weeks.
3. Pre-warm Gibco™ Opti-MEM™ medium to 37°C, let FuGENE® 6 Transfection Reagent come to RT

4. Remove DMEM medium from the HEK-293 cells in 10cm dishes, wash 1x PBS, add 10 ml of Opti-MEM™ medium to cells and incubate 20 min at 37°C.
5. In sterile Eppendorf tube, mix the 3.5 ug linearized DNA from step 1 and 500uL Opti-MEM™ medium.
6. Mix 20 uL FuGENE® 6 and 500uL Opti-MEM™ in a second tube (for 2 transfections = 40 uL and 1ml etc.)
7. Combine the DNA tube from Step 5 and the FuGENE® 6 tube from step 6, incubate 10' at room temperature.
8. Add transfection mix DROPOWISE to cells.
9. Incubate for 24h in Opti-MEM™, then exchange medium for selective medium: DMEM+ FCS + PeniStrep + both HygR and ZeoR.
10. Replace medium every 2-3 days to remove dead cells. Be careful not to wash off colonies.
11. Visualize developing colonies under fluorescent microscope to look for eYFP expression from pACEMam3/Integrator Module to identify best putative clones.

E. Appendix

E.1. Preparing bacterial stock from agar stabs

We recommend that you prepare your personal bacterial stock from the agar stabs you received in the kit or transform your laboratory strain of choice with the vectors (please note that for the donor vectors this needs to be a pir+ strain). This is advisable since agar stabs only have a limited shelf life.

To generate your bacterial stock for long-term storage, streak bacteria from the agar stab onto an appropriate selective plate (refer to the vector maps for acceptor and donor vectors) or plates without antibiotics (pirHC and pirLC strains; we recommend to test these strains against a panel of antibiotics to be on the safe side; no growth of colonies should be observed under conditions of antibiotic selection). Incubate the plates over night at 37°C and then proceed to prepare stocks from individual colonies for long-term storage according to your protocol of choice (glycerol, DMSO, etc.), as described, for example, in Inoue et al. (1990), Molecular Cloning (Sambrook and Russell, 2000), Current Protocols in Molecular Biology (Ausubel et al., 1994), etc.


E.2. MultiMam™ *Stable* vectors: maps, sequences, MCS, restriction

Note: All acceptor and donor vector sequences can be provided in electronic format. These sequences contain all relevant information such as unique restriction sites, oris, resistance markers, etc. that is also shown in the circle maps. Request your set of vector files and accompanying files from Geneva Biotech at contact@geneva-biotech.com.

Acceptor and donor vectors are presented as circle maps and, in addition, the multiple cloning site (MCS) of each vector is shown featuring relevant unique restriction sites. Moreover, you will find, for the purposes of designing a restriction strategy, a non-exhaustive list of restriction endonucleases that cut once, twice or not at all. Additional restriction sites can be identified with any sequence analysis software, e.g. SnapGene, VectorNTI, ApE, etc. or by using online tools such as WebCutter 2.0 (<http://rna.lundberg.gu.se/cutter2>) or the NEB cutter V2.0 (<http://tools.neb.com/NEBcutter2/>).

E.2.1 Acceptor vectors

E.2.1.1 pACEMam1: 3443 bp



Multiple Cloning Site (promoter to terminator)

BamHI	RsrII	BssHII	EcoRI	StuI	Sali
GGCTAGT	<u>GGATCC</u>	GGTCCGAAGCGCGGAAATTCAAAAGGCC	TACGT	CAGTGACGAGCT	CACTTTG
NotI	BstBI	XbaI	PstI	HindIII	
<u>CGCGGCCG</u>	<u>CTTCGA</u>	<u>ATCTAGAGC</u>	<u>CTGCAG</u>	<u>TCTCGACAAGCTT</u>	GTCGAGAAGTACTAGAGGA

Enzymes that cut pACEMam1 once (not exhaustive)

1	Age I	420	AlwNI	520	ApaLI	3254	AvrII
2801	BamHI , BstI	3231	BplI	114	BspHI	2867	BstBI
2816	BssHII	3266	BstXI	3260	BstZ17I	2074	Bsu36I
2101	Clal	1979	DraIII	2823	EcoRI	1224	EcoRV
2894	HindIII	3020	Hpal	3009	Mfcl	2128	MluI
1109	MscI	2510	Ncol	2383	Ndel	2859	NotI
2087	Pmel	2881	PstI	2103	Pvul	2807	RsrII
1166	SacII	2839	SalI	2907	Scal	2490	SnaBI
2833	StuI	2873	XbaI	1629			

Bold type: restriction enzymes cutting in the MCS

Enzymes that cut pACEMam1 twice (not exhaustive)

2839, 3260	AccI	2156, 2761	Asel / VspI	2714, 2845	BanII / SacI
949, 1418	BglII	1169, 2859	EagI	834, 1647	PciI
2095, 2149	SpeI				

Enzymes that do not cut pACEMam1 (not exhaustive)


Acc65I	AfII	Apal	Ascl	BbsI	BsaBI
DraII	EcoNI	Fsel	KasI	KpnI	Nael
NarI	Nhel	NruI	Nsil	PacI	Pfol
PvuII	SbfI	Sfil	Sfol	SmaI/XbaI	SphI
SrfI	SspI	XcmI	Xhol	XmnI	

Sequence

5'-
accgggtgacttgggtcaactgtcagacccaaggatcttaggtgaagatccatgtttttgcataatctcatgaccaaaatccctta
acgtgagtttcgttccactgagcgtcagaccccgtagaaaagatcaaaggatcttcttgagatcc
ttttttctgcgcgtaatctgctgctgcaaaaaaccaccgcgtaccagcggtggttgc
gccggatcaagagactaccaactctttccgaaggtaactggctcagcagagcgcagataccaaa
tactgttcttcttagtgcgttagttaggcaccactcaagaactctgttagcaccgcctacata
cctcgctctgctaattctgttaccagtggctgcccagtggcgataagtcgtgtctaccgggtt
ggactcaagacgatagttaccggataaggcgcagcggctggctgaacgggggttcgtgcacaca
gcccagctggagcgaacgacacctacaccaactgagatacctacagcgttagctatgagaaagcgc
cagcgtcccgaaaggagaaaaggcggacaggatccggtaagcggcagggtcggaaacaggagagc
cagcgggagacttcaggggaaacgcctggatctttatagtcgtcgggttcgtccaccc
acttgcgcgtcgtatggatgcgtcaggggggcggagcctatggaaaaacgcgcacacgc
ggccttttacggttctggccttgcgtggcttgcacatgttcttcctgcgttatcccc
tgattgacttgggtcgcttctgtggatgcgcagatccctgcgttagcgggtgtggcggaca
ataaagtcttaaactgaacaaaatagatctaaactatgacaataaagtcttaaactagacagaata
gttgtaaactgaaatcagtcgcgttatgcgtgaaaaaagcataactggactttgttatggctaaag
caaacttcttctgaagtgcacattggccgttgcgtattaaagagggcgtggccaagggcatg
taaagactatattcgcggcgttgtgacaattaccgaacaactccgcggccggaaagccatctcg
gcttgcacgaattgttaggtggcggacttgggtcgatataactgcacacttctccgtatg
cccaactttgtatagagagccactgcggatcgtcaccgtaatctgcgtcacgtagatcacataa
gcaccaagcgcgttggcctcatgcgttaggagattgatgagcgcggtgcaatgcctgcctccgg
tgctcgccggagactgcgcagatcatagatagatctcaactacgcggctgcgtcaactggcaga
acgtaaaggcgcagagcgcacaaaccgccttgcgtcaaggcagcaagcgcgtatgtctta
ctacggagcaagttcccgaggtaatcgagttccggctgtatgttggagtaggtggctacgtctccg
aactcaccgaccggaaaagatcaagagcagccgcattggattgacttggctcaggccgagcctacat
gtgcgaatgtatgcccataacttgagccacctaactttgttttagggcactgcctgcgtaca
tcgttgcgtgcgtaaacatcgttgcgtccataacatcaaaacatcgaccacggcgtacgcgc
ttgctgttggatgcccaggcatagactgtacaaaaaacagtctacaacaagccataaaaccgc
cactgcgcgttaccaccgcgtcggtcaagggttgcgttagcgcgtacgcgcatacgc
cttgcattacagttacgaaccgaacaggcttatgtcaactgggtcgtgccttcattccgttcca
cggtgtcggtcaccggcaacccttggcagcgcgtcaagggttgcgttagcgcgtacgcgcatacatta
tacgaagttatctgtactataacggcgttaaggtagcgttagttaaacacttagtgcgtatgcgc
gtacggccagatatacgcgttgcattgttgcgttagtattgacttagttataatagtaatcaattacgggg
tcattagttcatagccatataatggagttccgcgttacataactacgtaaatggcccctggc
tgaccggccaaacgaccccccgcattgcgtcaataatgcgtatgttcccatagtaacgccaata
gggactttccattgcgtcaatgggtggactattacgttaactgcccactggcagtagatcaa
gtgtatcatatgccaagtagcgccttattgcgtcaatgcgttaatggccgcctggcattat
gcccagtagatgcgttatggactttccctacttgcgttagcgtacatctacgtattatgcgt
accatgggtatgcgtttggcagtagatcaatggcgtggatagcgggtttactcaggggatt
ccaagtcgtccacccattgcgtcaatggagttttggcaccaaaatcaacgggactttcca
aatgtcgtaacaactccgcggccattgcgtcaatggcgtttttggcaccaaaatcaacgggactttcca
ataagcagagactctctggctactagagaacccactgcgtactgcgttatcgaaattaatcact
cactataqqqagacccaqctqgctagtqgatcccqgtccqaaqcqccqqaattcaaqqcctac

gtcgacgagctcaattgtcgccgcggcgttcaatcttagagcctgcagtctcgacaagcttgtcga
gaagtactagaggatcataatcagccataaccacattttagaggtttacttgcttaaaaaacct
cccacacccctccccctgaacctgaaacataaaatgaatgcaattttgttgcatttttttattgc
agcttataatggttacaataaagcaatgcacatcacaaatttcacaaataaagcatttttttact
gcattcttagttgtggttgtccaaactcatcaatgttatcatgtctggatctgatcactgct
tgagcctagaagatccggctgctaacaagccgaaaggaagctgagttggctgctgccaccgctg
agcaataactatcataaccctagggtataccatctaatttgaaccagataagtgaaatctagtt
ccaaactatttgtcatttttaatttcgtatttagcttacgacgctacacccagttcccatctatt
ttgtcactcttcctaaataatcctaaaaactccattccaccctccagttcccaactattt
gtccgcccaca -3'

E.2.1.2 pACEMam2: 4618 bp



Multiple Cloning Site (promoter to terminator)

SmaI					
BbsI	XbaI	XhoI	NcoI	NheI	PvuII
<u>G C G G C C G T C T C A G G C C A C C G A A G A C T T G A T C A C C C G G G A T C T C G A G C C A T G G T G C T A G C A G C T</u>					
KpnI					
NsiI	SphI	Acc65I			
<u>G A T G C A T A G C A T G C G G T A C C T A A</u>					

Enzymes that cut pACEMam2 once (not exhaustive)

2630	Acc65I	1	Age I	420	AlwNI	3573	Apal
520	ApaLI	4408	Asel, VspI	2688	BbsI	3278	BpI
4441	BstXI	4417	BstZ17I	1224	EcoRV	888	FspI
2630	KpnI	1109	Mscl	2661	Ncol	2654	NheI
2643	NsiI	2339	PflMI	2087	Pmel	2649	PvuII
2675	SmaI, XmaI	4076	SnaBI	4421	Spel	2636	SphI
3120	Sse232I	2667	Xhol, Scil				

Bold type: restriction enzymes cutting in the MCS

Enzymes that cut pACEMam2 twice (not exhaustive)

3478, 3640	Afel	114, 2509	BspHI	2967, 3010	Bbel, KasI, NarI, SfoI
2964, 3121	Nael	1166, 3405	SacII		

Enzymes that do not cut pACEMam2 (not exhaustive)

AflII	Ascl	AvrII	BamHI	BclI	BsaBI
BspEI	BstBI	ClaI	EcoNI	EcoRI	FseI


HindIII	HpaI	MfeI	MluI	NotI	NruI
PacI	PstI	PvuI	RsrII	SacI	SalI
SbfI	Scal	SfiI	SgfI	SrfI	SspI
StuI	XbaI	XcmI	XmnI		

Sequence

5' -

gatttgggacaaaggaagtccctgcgcctctcgcacgattaccataaaaggcaatggctgcggct
cgccgcgcctcgacagccgcggcgtccggggccgcgcgcgcgcgcgcgcgcgcgcgcgcgc
cgaggcggcc
gcgcacgcggccgcacggagccccgcacccgaagccggccgtgtcagcaactcggggaggggg
tgcaggggggggttacagccccgaccgcgcgcccacacccctgtcaccacccacacacc
ccgcacgcagccttgcgtccctcgacgcgcgcacaaagccccgcgcgcgcgcgcgcgc
ccctcgccgcacacgcggagcgacacacacacacacacacacacacacacac
gcgcggccgcacgcggcgctccccacgcacacacacacacacacacacac
cgcacaaaggccctccggagcccttaaggcttcacgcagccacagaaaagaaacgagccgtc
attaaaccaagcgctaattacagccggaggagaaggccgtccgcgcgcgcacctgtggagta
acgcggtcagttagagccggggcggcgcgaggcggcgagcggggcagggcgaaggca
acgcagcgactccgcggcgcttcgttttataggccgcgcgcgcgcgc
taaaagaaaactttcgagcgcgcgcgtctgattggctgccgcgcgcgcgcgc
ccgc
caaaataaaaaataaaataacaaaattgggggtgggagggggggagatgggagagtg
aagcagaacgtgggctcacctcgacccatgagtaatacgatgactatacgatgtactgcc
aagtaggaaaagtccataaggcatgtactggcataatgccaggcggccattaccgtcattga
cgtcaataggggcgtacttgcatactgatgtactggccaaatgtggcagttaccgt
aatagtccacccattgacgtcaatgaaaagtccattggcgttactatggaaacatacgatcatta
ttgacgtcaatggcgggggtcggtggcggtcagccaggcggccattaccgttaagttatgtaa
cgcggaactccatatatggctatgactaatgacccgtattgattactattaataacgtatac
tagtacgttagtacgtccatctaattgaaaccagataagtgaaatctagttccaaactatgg
tcatttttaatttcgtatttagcttacgacgtacaccagttcccatctatttgtcactctcc
ctaaataatcctaaaaactccattccacccctccagttccaaactatggtccgcccaca -
3'

E.2.1.3 pACEMam3/Integrator Module: 6954 bp




accggttgacttgggtcaactgtcagaccaagttactcatatatacttagattgattaaaacttcattttatattaaaggatctaggtaagat
ccttttataatctcatgacaaaatccctaacgtgagtttcgttccactgagcgtcagaccccgtagaaaagatcaaaggatcttgcgatcc
ttttttctgcgtaatctgtgttgcacaaaaaccaccgcgtaccagcggtttgttgcggatcaagagactaccactttttccgaa
ggtaactggcttcagcagagcgcagataccaaatctgttcttagtgttagccgtagtttaggccaccactcaagaactctgttagcaccgcctaca
tacctcgctcgtaatccgttaccagtggctgtccagtggtccataactcggttaccgggtggactcaagacgatagttaccggataaggc
gcagcggtcggtgaacgggggtcgcacacagcccagctggagcgaacgcacctacaccgaactgagataacctacagcgtgagctatga
gaaagcgccacgctccgaagggagaaaggcggacaggtatccgttaagcggcagggtcggaacaggagagcgcacgaggagcttccagg
gggaaacgcctgttatctttagtccgtgggttcgcacccctctgacttgagcgtcattttgtatgctcgtagccccggcggctatgga
aaaacgccagcaacgcggcttttacggttccgtggctttgtcacaatgttctcggttatccctgattgactgggtcgct
ttcctgtggatgcgcacagacatgataagatacattgtgagttggacaaccacaactagaatgcagtaaaaaatgcttatttgaaattt
gtgatgttattgttaccattataagctgcaataaacaagttgggtggcgaagaactccagcatgagatccccgcgtggaggatca
tccagccggcgtccggaaaacgattccgaagccaaaccttcatagaaggcggcggtaatcgaaatctgttagcactgtcagtcgt
cgccacgaagtgcacgcagttccggccgggtcgccagggcgaactccgcggccacggctgtcgccgtatcggtcatggccggccggag
gcgtccggaaagttcggtggacacgaccctccgaccactcggcgtacagctcgccaggccgcacccacaccaggccagggttgcggcacc
acctggcgtccggaccgcgtatgaacagggtcacgtcgccggaccacaccggcgaagtcgtccacgaagtccggagaacccgagccg
gtcggccagaactcgaccgctccggcagtcgcgcggtagcaccggacggactggtaacttggccatggtttagtccctcacattgtcg

gccgggtgcagatgaacttcagggtcagttgccntaggtggcatgccctgcccgcggacacgctaacttgtggccttacgtcgccgt
tccagctgaccaggatgggcaccaccccggtacaagctcctcgccctgctaccatggctcgagatccgggtgatcaagtctcggtggctg
agacggccgcaattttgccaatgtgagacagcacaacaaccagcacgttgcccaggagctgttagaaaaagaagaaggcatgaacatg
gttagcagaggcttagcagcccggtcacacgcagaagccgaaccccgccctgccccgtccccccgaaggcagccgtccccctgcggcagc
cccgaggctggagatggagaaggggacggcgccggcggcggcggcggcggcggcggcggcggcggcggcggcggcggcggcggcggc
cgccggccgttagaggggtgcggcgccctccagattcggctccggcagattgggacaaggaaagtccctgcgcctctgcacgattacca
taaaaggcaatggctgcggctccgcgcctcgacagccgcggcgctccggggccgcgcgcgcgcgcgcgcgcgcgcgcgcgcgc
ccccggccggccggcaccctgc
ggccgtgctcagcaactcggggaggggggtgcaggggggttacagcccgaccgcgcgcgcgcgcgcgcgcgcgc
ccccgcacgcagccttgc
gc
cgctccccccgcacaaaggccctccggagcccttaaggcttcacgcagccacagaaaagaaacgagccgtattaaaccaagcgcata
tacagcccgaggagaagggccgtccgcgcgcgcgcgcgcgcgcgcgcgcgcgcgcgcgcgc
gcggggcacgggcaaggcaacgcagcactccgcgcgcgcgcgcgcgcgc
aacttcggagcgcgcgcgcgcgcgcgcgcgcgcgcgcgcgcgc
ccccccccccgcgcgcgcgcgcgcgcgcgcgcgcgcgcgc
agcagaacgtgggctcacctgacccatgagtaagcgatgactaatacgtagatgtactgccaagtaggaaagtcccataaggtcatgtact
ggcataatgccaggcggccattaccgtcattgacgtcaatagggccgtacttgcatactgatgtactgccaagtggcagtt
ccgtaaatagtccacccattgacgtcaatggaaagtccctattggctactatggAACATACTGTCATTGACGTCAATGGCGGGGTCGTT
ggcggcgtcagccaggcggccattaccgttaactgtacgcggactccatataatggctatgaactaatgacccgtattgattactattaa
aacgtatactgtatcgatccatctaattggAACAGATAAGTGAATCTAGTTCAAAACTCCATTCCACCCCTCCAGTTCCAACATTGTCGCC
acgacgtacaccagttccatctatttgcactttccaaataatcctaaaaactccattccacccctccagttccaaactatttgcgc
caca

E.2.2 Donor vectors

E.2.2.1 pMDC: 2889 bp



Multiple Cloning Site (promoter to terminator)

BamHI	RsrI	BssHII	StuI	SalI
AGACCCAAGCTGGCTAGT	<u>GGATCCCGTCCGAAGCGCGCGGAATTCAAAAGGCCTACGTCGAC</u>			
SacI	XbaI	PstI		
<u>GAGCTCACTAGTCGCGGCCGCTTCGAATCTAGAGCCTGCAGTCACGACAA</u>				

Enzymes that cut pMDC once (not exhaustive)

1302	AccIII, BspEI	54	Acc65I	693	Age I	1723	AvrII
2176	BamHI	1682	BglII	2161	BssHII	5	BstXI
643	Bsu36I	2877	Clal	1957	Hpal	54	KpnI
1968	Mfel	2849	MluI	1033	MscI	2871	NruI
2096	PstI	2169	RsrII	58	SacII	2138	Sall
988	SspI	2146	StuI	2104	XbaI		

Bold type: restriction enzymes cutting in the MCS

Enzymes that cut pMDC twice (not exhaustive)

768, 2110	BstBI	61, 2118	BstZI, EagI	1298, 2154	EcoRI
349, 2083	HindIII	997, 2467	Ncol	60, 2117	NotI
1634, 1668	PflMI	316, 1937	PsiI	573, 1400	PvuII
2132, 2263	SacI	883, 2070	Scal	107, 2489	SnaBII


Enzymes that do not cut pMDC (not exhaustive)

Afel	AflII	AlwNI	Apal	Ascl	BbvI
BbsI	BclI	BspHI	BstZ17I	DraI	EcoNI
EcoRV	FseI	FspI	KasI	Nael	NarI

Nhel	Nsil	Pacl	Pmel	Pvul	Sbfl
Scil	Sfil	Sgfl	Smal	Sphl	Xcml
Xhol	Xmal	Xmn1			

Sequence

E.2.2.2 pMDK: 4130 bp



Multiple Cloning Site (promoter to terminator)

BbsI	ScI I
NsiI	XbaI
<u>GC GGG CCG TCT CAGGCCACC</u>	
<u>GAAGACTT GATC ACCCGGGATCTCGAGCCATGGTGCTAGCAGCT</u>	
Acc65I	NcoI
KpnI	NheI
<u>GATGCATAGCATGCGGTACCTAA</u>	

Enzymes that cut pMDK once (not exhaustive)

2904	Acc65I, KpnI	3967	AlwNI	1961	Apal	1100	AvrII
3025	BspHI	899	BstBI	3453	BstXI	1117	BstZ17I
2919	Bsu36I	1107	ClaI	318	FspI	3746	HindIII
298	Mscl	2873	Ncol	2880	NheI	2891	NsiI
3190	PflMI	3445	Pmel	267	PstI	733	RsrII
2129	SacII	1113	SphI	27	XcmI	2867	XbaI

Bold type: restriction enzymes cutting in the MCS

Enzymes that cut pMDK twice (not exhaustive)

1894, 2056	Afel	1126, 3668	Asel	54, 2990	BglII
993, 1954	Pfol	1055, 2859	SmaI, XmaI	1458, 3504	SnaBI
619, 2898	SphI				

Enzymes that do not cut pMDK (not exhaustive)

AccIII	AclI	AflIII	AgeI	ApaLI	Ascl
BamHI	BclI	BspEI	EcoNI	EcoRI	EcoRV
FseI	HpaI	MfeI	MluI	NotI	NruI
PacI	PvuI	SacI	Sall	SbfI	Scal

Sfil Sgfl Sspl StuI XbaI XmnI


Sequence

5' -

aagtaaaactggatggctttcttgcggccaaggatctgatggcgcaagggatcaagatctgatcaag
agacagatgaggatcggttcgcattgaacaagatggattgcacgcaggctccggccgctt
gggtggagaggctattcggtatgactggcacaacagacaatcggtctgtatgccggcgtgt
tccggctgtcagcgcaggggcgccggctctttgtcaagaccgtccgggtgcgcagctgtgc
aactgcaggacgaggcagcgcggctatcggtctggccacgacggcggtcgcagctgtgc
tcgacgttgtcactgaagcgaaaaggactggctgtattggcgaagtgcggggcaggatctcc
tgtcatctcacctgcgtccgcgagaaagtatccatcatggctgtatgcataatgcggcgctgcata
cgcttgcgtccgcgtacctgcccattcgaccacaagcgaacatcgcatcgagcagcacgtactc
ggatggaagccggcttgcgtcattcgcgtcaggatgttgcgcgaaagagacatcaggggctcgccagccg
aactgttcgcaggctcaaggcgcgcattgcggcaggatctcggtgtacacatggcgtat
cctgctgcgaatatcatgtggaaaatggcgctttctggattcatcgactgtggccggctgg
gtgtggcgaccgctatcaggacatagcgttgctaccgtatattgtgaagagacttggcgcgc
aatgggctgaccgcttcgtgtttacggatcgccgtcccgattcgacgcgcgcgcgcgc
atcgccctttgcgtcggactttctgagcgggactctgggttcgaaatgaccgaccaagcgcacgc
caacctgcgcattcaggatccgcgttgcgcgcgcgcgcgcgcgcgcgcgcgcgc
tttccggacgcggcgtggatgtatccgcgcgggatctcatgcgtggagttctcgccccaccc
cgggatctatgtcgggtcgccgagaaagaggtaatgaaatggcaccttaggtatcgataactgtata
gttattaatagtaatcaattacgggtcattagttcatagcccatatatggagttccgcgttacat
aacttacggtaaatggccgcctggctgaccgcgcgcgcgcgcgcgcgcgcgc
cgtatgtcccatagtaacgcgcgcgcgcgcgcgcgcgcgcgcgcgcgcgcgc
aaactgcccacttggcagtacatcaagtgttatcatatgcgcgcgcgcgcgcgcgc
acggtaatggccgcctggcattatgcgcgcgcgcgcgcgcgcgcgcgc
acatctacgtatttagtcatcgctattactcatgggtcgagggtgagccccacgttctgc
ccccatctccccccctccccaccccaattttgtatttatttttaattattttgtc
gatggggcggg
cgaggcggagaggtgcggcggcagccaatcagagcggcgcgcgcgcgc
ggcggcggcggcggcggcggcggcggcggcggcggcggcggcggcggcggcggc
cgccccgtgccccgtccgcgcgcgcgcgcgcgcgcgcgcgcgc
cacaggtgagcggcggcggcggcggcggcggcggcggcggcggcggc
tcgtttcttctgtggctgcgtgaaagcctaagggtccggagggccctt
agcggctcgggggggtgcgtgcgtgtgtgcgtggggagcgcgcgc
gcggctgtgagcgcgcgcggcggcggcggcggcggcggcggcggc
ggccggggggcggcggcggcggcggcggcggcggcggcggcggc
tgcgtgggggggtgagcaggggggtgtggcgcggcggcggcggc
tccccgagttgctgagcacggccgcgttcgggtgcgggctcc
cgccgtgcgggggggggggggggggggggggggggggggggg
ggagggctcgggggagggggcgccggccggccggccgg
agccattgcctttatggtaatcgtgcgcgcgcgcgc
agccgaaatctgggaggcgcgcgcgcgcgc
caggaaggaaatggcggggagggcgcgcgcgcgc
gcctcgccgcgcgcgcgcgcgcgcgcgcgc
tggcgtgtgaccggcggcgtctagagcctctgc
gctcctggcaacgtgcgtgtgtgc
ggccaccgaagactgtatcacccggatctcg
gtacctaattcactcctcaggcgcgcgc
tggctacaaataccactgagatctt
ttgagcatctgactctggctaataaggaaattt
tgtgtctcactcggaaaggacatatggg
ggggcaaattt
aaaacatcagaatcagaatc
gagacttgg

ttagatggcaacatatgccatgtggctgccatgaacaaagggtggctataaagaggcat
cagtatatgaaacagccccctgctgtccattccttattccatagaaaagccttgactgaggttag
attttttatattttgtttgttgttatttttttttaacatccctaaaatttccttacatgtt
ttactagccagatttccctctccctgactactcccagtcatagctgtccctttctttatga
agatccctcgacgtttaaccatgtgcctggcagataactcgataatgtatgtctatacgaagt
tatggtacgtactaagctctcatgtttcacgtactaagctctcatgtttaacgtactaagctctca
tgtttaacgaactaaaccctcatggctaactgactaagctctcatggctaactgactaagctctca
tgtttacgtactaagctctcatgtttgaacaataaaatataatcagcaactaaatagcc
tctaagggttttaagtttataagaaaaaaaaaaaaaatataaggctttaaagcttttaagggtttaa
cggttggacaacaaggccaggatgtaacgcactgagaagcccttagagcctctcaaagcaattt
tcagtgacacaggaacacttaacggctgacagaattagcttcacgctgccgcaagcactcaggcg
caaggcgtctaaaggaagcggAACACGTAGAAAGCCAGTCCGAGAAACGGTGTGACCCCGAT
gaatgtcagctactggctatctggacaaggaaaacgcaagcgcAAAGAGAAAAGCAGGTTAGCTG
cagtggcttacatggcgatagctagactggcggtttatggacagcaagcgaaccggaaattgcc
agctggggcgccctctggtaagggtggaaagccctgca-3'

E.2.2.3 pMDS: 4088 bp



Multiple Cloning Site (promoter to terminator)

BbsI	XbaI	SmaI	XbaI	NcoI	NheI
Acc65I	<u>GAAGACTT</u>	<u>GATCACCCGGG</u>	<u>ATCTCGAGCC</u>	<u>ATGGTGCTAGCAGCT</u>	
NsiI	SphI	KpnI			
<u>GATGCATAGCATGCGGTACCTAA</u>					

Enzymes that cut pMDS once (not exhaustive)

1804	Acc65I, KpnI	2988	AgeI	861	ApaI	3495	ApaLI
4080	AvrII	1746	BbsI	1890	BgIII	3380	BspEII
2353	BstXI	17	BstZ17I	4087	Clal	2646	HindIII
1773	Ncol	1780	NheI	1791	NsiI	2090	PflMI
2345	Pmel	2613	PsI	3598	PvuI	1029	SacII
1767	ScI	1759	SmaI, XmaI	13	Spel	1798	SphI
1312	Sse232I	1767	XbaI				

Bold type: restriction enzymes cutting in the MCS

Enzymes that cut pMDS twice (not exhaustive)

794, 956	Afel, Vspl	26, 2568	Asel	1424, 1467	Bbel, NarI
1925, 3220	BspHI	1819, 2938	Bsu36I	1012, 1728	EagI
1785, 2868	PvuII	358, 2404	SnaBI		

Enzymes that do not cut pMDS (not exhaustive)

AclI	AlwNI	Ascl	BamHI	BclI	BsaBI
BspEI	BstBI	EcoNI	EcoRI	EcoRV	Fsel
FspI	HpaI	MfeI	MluI	MscI	NotI
NruI	PacI	PmlI	PstI	RsrII	SacI
Sall	SbfI	Scal	SfiI	SgfI	StuI
XbaI	XcmI	XmnI			

Sequence

5' -

catactacgatactagtatacgttattaaatagtaatcaattacgggtcattagttcatagccca
tatatggagttccgcgttacataactacggtaatggccgcctggctgaccgcccacgcaccc
cgcccattgacgtcaataatgacgtatgttccatagtaacgccaataggactttcattgacgt
caatgggtggactattacggtaactgcccacttggcagtacatcaagtgtatcatatgccaagt
acgccccctattgacgtcaatgacgttaatggccgcctggcattatgcccactacatgaccta
tgggactttcacttggcagtacatctacgtattagtcatcgcttactatctatgggtcgaggta
gccccacgttctgcttcaactctcccatctccccccatctcccccaccccaatttgcatttattta
tttttaattatgtgcagcgatgg
cgggggcgaggg
cgaaaagttcctttatggcgaggcggcggcggcggccctataaaaagcgaagcgcgcggcgg
gcgggagtcgtgcgtgcctcgccccgtgccccgtctccgcgcgcgcgcgcgcgcgc
ctctgactgaccgcgttactccacaggtgagcggcgggacggcccttcctccgggctgttaat
tagcgcttggttaatgacggctcgttttctgtgcgtgaaagccttaaaggctccgg
gagggcccttgcggggggagcggctcggggggtgcgtgcgtgtgcgtggggagcgc
cgcggtgcggccgcgtgcggcggtgtgagcgctgcggcgcggcggggcttgcgc
cgcggtgcgcgaggggagcgcggccgggggggggggggggggggggggggggggg
caaaggctgcgtgcgggtgtgcgtgggggtgagcagggggtgtggcgcggcggcgg
gtaaaccccccctgcaccccccctcccgagttgcgtgagcacggccggcttcgggtgcgg
gtgcggggcggtggcgccgggctcgccgtgcgggggggggggggggggggggg
ggcgccggccgcctcgggcgggggggggggggggggggggggggggggggggg
ctgtcgaggcgcggcgagccgcagccattgcctttatgttaatcgtgcgagaggcgc
tcctttgtcccaatctggcgagccaaatctgggaggcgccgcacccctctagcg
ggcgaagcggtgcggcgccggcaggaaggaaatgggggggggggggggggggg
gccgtcccttcctccatctccagcctcggggtgcgcagggggacggctgc
ggcagggcggggttcggcttcgggtgtgaccggcggtgcgtgcgc
atgccttccttttcctacagctcggcaacgtgcgtgtgtgc
gcaaagaattgcggccgtcaggccaccgaagacttgc
actgcgtatgcatacgatgcgttacctaattcactc
gtggctgggtgtggctaattccctggctcacaaataccact
tatggggacatcatgaagcccttgagcatctgacttgc
gcaatagtgttgcattttgtctactcg
aaacatcagaatgagttggtaggttgc
aagggtgcataaagaggcatcgat
aaaagccttgacttgc
cctaaaatttccttacatgtttact
agctgc
tataatgtatgcata
tgttaacgtacta
tggcta
taaatcagcaact
MultiMam™ Stable

ttttaagctttaaggtaacggtgtggacaacaagccaggatgtacgcactgagaagccc
tttagccctctcaaagcaatttgagtgacacaggaacacttaacggctgacataatcagctca
cgctgcgcgaagcactcaggcgcaaggctgctaaaggaagcgaacacgtagaaagccagtcgg
cagaaacggtgctgaccggatgaatgtcagctgggaggcagaataatgatcatatcgtcaatt
attacccacggggagagcctgagcaaactggctcaggcattgagaagcacacggtcacactg
cttccggtagtcaataaaccggttaagttagcgtatgcgcacgcactggccagaacacctgaccg
aacgcagcggtggttaacggcgactggcggtttcatggctttagactgtttttgggtac
agtctatgcctcgccatccaagcagcaagcgcgttacgccgtggcgtatgtttagttatgga
gcagcaacgatgttacgcagcaggcagtcgcctaaaacaaaggtaaacatcatgagggaaagcgg
tgatcggcgaagtatcgactcaactatcagaggttagtggcgtcatcgagcgcacatcgaaccga
cggtgctggcgtacattgtacggctccgcgtggatggcgcctgaagccacacagtgtatattg
atttgctggtaacggtaaggctgatgaaacaacgcggcgagctttagtcaacgaccctt
tggaaacttcggctccctggagagagcgagatttcgcgcgttagaagtaccattgttgc
acgacgacatcattccgtggcgttatccagctaagcgcgaactgcaattggagaatggcagcgc
atgacattctgcaggtatctcgagccagccacgatcgacattgatctggctatctgctgacaa
aagcaagagaacatagcgtgccttggtaggtccagcggggagaactctttagtccgtct
aacaggatctatttggggcctaattgaaacccctaacgcgtatggactcggccggactggcgt
gcgtatggcgtatgttagtgcgttgcgcactggcaatggagcgcgttgcgcgtatcagccgt
cgccgaaggatgtcgcgtgcgcactggcaatggagcgcgttgcgcgtatcagccgt
ttgaagctagacaggcttatcttggacaagaagaagatcgcttgcctcgccgcagatcagttgg
aagaatttgcactacgtgaaaggcgagatcaccaaggttagtggcaataatgtctaacaattc
gttcaagccgacggatctatgtcgggtgcggagaaagaggtaatgaaatggcacctaggtat -3'

F. References

1. **Alberts B** (1998). The cell as a collection of protein machines: preparing the next generation of molecular biologists. *Cell* 92: 291-294.
2. **Ausubel F, Brent R, Kingston RE, Moore DD, Seidman JG, Smith JA, and Struhl K** (eds., 1994). Current Protocols in Molecular Biology. John Wiley & Sons, New York, electronic version DOI 10.1002/0471142727
3. **Bieniossek C, Nie Y, Frey D, Olieric N, Schaffitzel C, Collinson I, Romier C, Berger P, Richmond TJ, Steinmetz MO, Berger I** (2009). Automated unrestricted multigene recombineering for multiprotein complex production. *Nature Methods* 6: 447-450.
4. **Charbonnier S, Gallego O, and Gavin AC** (2008). The social network of a cell: Recent advances in interactome mapping. *Biotechnology Annual Review* 14: 1-28.
5. **Ehmsen J, Poon E, and Davies K (2002)**. The dystrophin-associated protein complex. *Journal of Cell Science* 115: 2801-2803.
6. **Figeys D** (2008). Mapping the human protein interactome. *Cell Research* 18: 716-724.
7. **Imasaki T, Calero G, Cai G, Tsai K-L, Yamada K, Gardelli F, Erdjument-Bromage H, Tempst P, Berger I, Kornberg GL, Asturias FJ, Kornberg RL, and Takagi Y** (2011). Architecture of the Mediator head module. *Nature* 475: 240-245.
8. **Inoue H, Nojima H and Okayama H** (1990). High efficiency transformation of *Escherichia coli* with plasmids. *Gene* 96: 23-28.
9. **Robinson CV, Sali A, and Baumeister W** (2007). The molecular sociology of the cell. *Nature* 450: 973-982.
10. **Sambrook J and Russell DW** (2000). Molecular Cloning, A Laboratory Manual, 3rd edition. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, available online at <http://cshprotocols.cshlp.org>
11. **Trowitzsch S et al.** (2010). New baculovirus expression tools for recombinant protein complex production. *Journal of Structural Biology* 172: 45-54, epub Feb 21, 2010, doi: 10.1016/j.jsb.2010.02.010
12. **Vidal M, Cusick ME, and Barabási AL** (2011). Interactome networks and human disease. *Cell* 144: 986-98.
13. **Vijayachandran LS, Viola C, et al.** (2011). Robots, pipelines, polyproteins: Enabling multiprotein expression in prokaryotic and eukaryotic cells. *Journal of Structural Biology* 175: 198-208.

We thank Dr. Imre Berger and his team from EMBL Grenoble for their input and assistance in preparing this manual.

NOTES:

G. Purchaser Notification

Limited Use Label License : Geneva Biotech

The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product in research conducted by the buyer (whether the buyer is an academic or for-profit entity).

The buyer cannot sell or otherwise transfer (a) this product (b) its components or (c) materials made using this product or its components to a third party or otherwise use this product or its components or materials made using this product or its components for Commercial Purposes. The buyer may transfer information or materials made through the use of this product to a scientific collaborator, provided that such transfer is not for any Commercial Purpose, and that such collaborator agrees in writing (a) not to transfer such materials to any third party, and (b) to use such transferred materials and/or information solely for research and not for Commercial Purposes.

Commercial Purposes means any activity by a party for consideration and may include, but is not limited to: (1) use of the product or its components in manufacturing; (2) inclusion of the product as part of another product; (3) use of the product or its components to provide a service, information, or data; (4) use of the product or its components for *ex vivo* or *in vivo* therapeutic, diagnostic, prophylactic or other unauthorized commercial purposes; (5) use in foods, drugs, devices or cosmetics of any kind, or for consumption by or use in connection with or administration or application to humans or animals; (6) resale of the product or its components, whether or not such product or its components are resold for use in research, or (7) any use other than research use.

For products that are subject to multiple limited use label licenses, the terms of the most restrictive limited use label license shall control. Geneva Biotech will not assert a claim against the buyer of infringement of patents owned or controlled by Geneva Biotech which cover this product based upon the manufacture, use or sale of a therapeutic, clinical diagnostic, vaccine or prophylactic product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product.

If the purchaser does not agree with the terms or limitations of this limited use agreement, the customer can return the product at their own costs but for a full refund (excluding shipping, tax and handling fees).

For information about purchasing a license to use this product or the technology embedded in it for any use other than for research use please contact Geneva Biotech at contact@geneva-biotech.com